Status: Not yet recruiting
A Prospective, Multicenter, Phase III Clinical Evaluation of the Safety and Efficacy of NH002 as a Contrast Agent Administrated Via Intravenous Bolus Injection and Infusion for Subjects Undergoing Cardiac Echocardiography
This is a phase III, prospective, multicenter, open-label, crossover study of the safety and efficacy of NH002-enhanced echocardiography in adult subjects with suboptimal images on non-contrast 2D transthoracic echocardiography with harmonic imaging within 30 days ahead of NH002 administration. The efficacy for two different modes of administration (i.e., IV bolus injection and infusion) will be evaluated independently.
Participants needed: 150
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Trust Bio-sonics, Inc.Updated: Jul 31, 2026
Eligibility criteria
18 years of age or older [+3]
ongoing or recent acute coronary syndrome within 6 months [+14]